A new variant of the novel coronavirus called EG.5 is spreading in Japan, with experts expecting it to be the dominant strain in the country by mid-September. Though there is no evidence that EG.

Arcturus Therapeutics (ARCT) had a challenging fourth quarter, with revenue and earnings falling short of analyst ...

Arcturus Therapeutics and CSL's COVID-19 vaccine Kostaive has been approved ... 1 subtype of Omicron variant BA.2.86, which is still one of the main strains currently circulating in Europe.

The European Commission (EC) has approved CSL and Arcturus Therapeutics’ COVID-19 vaccine Kostaive (ARCT-154) for use in individuals aged 18 years and older. The decision follows a recent ...

Arcturus received approval from the European Commission (EC) in February for KOSTAIVE, the world’s first approved sa-mRNA COVID-19 vaccine. The centralized marketing authorization of KOSTAIVE ...

As COVID-19 ... virus variants, the likelihood of optimizing KOSTAIVE's formulation and completing technical enhancements, and the impact of general business and economic conditions. Arcturus ...

As COVID-19 ... virus variants, the likelihood of optimizing KOSTAIVE’s formulation and completing technical enhancements, and the impact of general business and economic conditions. Arcturus ...